Literature DB >> 26010453

Quantification of myo-inositol, 1,5-anhydro- D-sorbitol, and D-chiro-inositol using high-performance liquid chromatography with electrochemical detection in very small volume clinical samples.

Karen J Schimpf1, Claudia C Meek2, Richard D Leff2, Dale L Phelps3, Daniel J Schmitz1, Christopher T Cordle1.   

Abstract

Inositol is a six-carbon sugar alcohol and is one of nine biologically significant isomers of hexahydroxycyclohexane. Myo-inositol is the primary biologically active form and is present in higher concentrations in the fetus and newborn than in adults. It is currently being examined for the prevention of retinopathy of prematurity in newborn preterm infants. A robust method for quantifying myo-inositol (MI), D-chiro-inositol (DCI) and 1,5-anhydro- D-sorbitol (ADS) in very small-volume (25 μL) urine, blood serum and/or plasma samples was developed. Using a multiple-column, multiple mobile phase liquid chromatographic system with electrochemical detection, the method was validated with respect to (a) selectivity, (b) accuracy/recovery, (c) precision/reproducibility, (d) sensitivity, (e) stability and (f) ruggedness. The standard curve was linear and ranged from 0.5 to 30 mg/L for each of the three analytes. Above-mentioned performance measures were within acceptable limits described in the Food and Drug Administration's Guidance for Industry: Bioanalytical Method Validation. The method was validated using blood serum and plasma collected using four common anticoagulants, and also by quantifying the accuracy and sensitivity of MI measured in simulated urine samples recovered from preterm infant diaper systems. The method performs satisfactorily measuring the three most common inositol isomers on 25 μL clinical samples of serum, plasma, milk, and/or urine. Similar performance is seen testing larger volume samples of infant formulas and infant formula ingredients. MI, ADS and DCI may be accurately tested in urine samples collected from five different preterm infant diapers if the urine volume is greater than 2-5 mL.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  LC; clinical samples; diapers; inositol; sorbitol

Mesh:

Substances:

Year:  2015        PMID: 26010453      PMCID: PMC4604022          DOI: 10.1002/bmc.3470

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  22 in total

1.  The inositol content of foetal blood and foetal fluids.

Authors:  J D CAMPLING; D A NIXON
Journal:  J Physiol       Date:  1954-10-28       Impact factor: 5.182

Review 2.  Roles for inositol polyphosphate kinases in the regulation of nuclear processes and developmental biology.

Authors:  Andrew M Seeds; Joshua P Frederick; Marco M K Tsui; John D York
Journal:  Adv Enzyme Regul       Date:  2007-01-05

3.  Postnatal inositol levels in preterm infants.

Authors:  J D Carver; C I Stromquist; V J Benford; G Minervini; S A Benford; L A Barness
Journal:  J Perinatol       Date:  1997 Sep-Oct       Impact factor: 2.521

4.  Analysis of inositol by high-performance liquid chromatography.

Authors:  W T Wang; J Safar; D Zopf
Journal:  Anal Biochem       Date:  1990-08-01       Impact factor: 3.365

5.  Myoinositol in human neonates: serum concentrations and renal handling.

Authors:  L M Lewin; S Melmed; J H Passwell; Y Yannai; M Brish; S Orda; H Boichis; H Bank
Journal:  Pediatr Res       Date:  1978-01       Impact factor: 3.756

6.  1,5-Anhydro-D-glucitol--a novel type of sugar in the human organism.

Authors:  E Pitkänen
Journal:  Scand J Clin Lab Invest Suppl       Date:  1990

7.  Inositol supplementation in premature infants with respiratory distress syndrome.

Authors:  M Hallman; K Bry; K Hoppu; M Lappi; M Pohjavuori
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

8.  Respiratory distress syndrome and inositol supplementation in preterm infants.

Authors:  M Hallman; A L Järvenpää; M Pohjavuori
Journal:  Arch Dis Child       Date:  1986-11       Impact factor: 3.791

9.  D-chiro-inositol metabolism in diabetes mellitus.

Authors:  R E Ostlund; J B McGill; I Herskowitz; D M Kipnis; J V Santiago; W R Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 10.  Inositol pyrophosphates: metabolism and signaling.

Authors:  M Bennett; S M N Onnebo; C Azevedo; A Saiardi
Journal:  Cell Mol Life Sci       Date:  2006-03       Impact factor: 9.261

View more
  3 in total

1.  Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.

Authors:  Dale L Phelps; Robert M Ward; Rick L Williams; Tracy L Nolen; Kristi L Watterberg; William Oh; Michael Goedecke; Richard A Ehrenkranz; Timothy Fennell; Brenda B Poindexter; C Michael Cotten; Mikko Hallman; Ivan D Frantz; Roger G Faix; Kristin M Zaterka-Baxter; Abhik Das; M Bethany Ball; Conra Backstrom Lacy; Michele C Walsh; Waldemar A Carlo; Pablo J Sánchez; Edward F Bell; Seetha Shankaran; David P Carlton; Patricia R Chess; Rosemary D Higgins
Journal:  Pediatr Res       Date:  2016-04-13       Impact factor: 3.756

Review 2.  Isolation, Separation, and Preconcentration of Biologically Active Compounds from Plant Matrices by Extraction Techniques.

Authors:  Victoria Raks; Hossam Al-Suod; Bogusław Buszewski
Journal:  Chromatographia       Date:  2017-09-22       Impact factor: 2.044

Review 3.  The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Reza Tabrizi; Vahidreza Ostadmohammadi; Kamran B Lankarani; Payam Peymani; Maryam Akbari; Fariba Kolahdooz; Zatollah Asemi
Journal:  Lipids Health Dis       Date:  2018-05-24       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.